The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBraveheart Inv Regulatory News (BRH)

Share Price Information for Braveheart Inv (BRH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7.25
Bid: 7.00
Ask: 7.50
Change: 0.50 (7.41%)
Spread: 0.50 (7.143%)
Open: 6.75
High: 7.25
Low: 6.75
Prev. Close: 6.75
BRH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Posting of annual report and notice of AGM

5 Jul 2023 07:00

RNS Number : 9488E
Braveheart Investment Group plc
05 July 2023
 

5 July 2023

Braveheart Investment Group plc

("Braveheart", the "Company" or the "Group")

 

Posting of annual report and accounts, notice of AGM and

proposed amendment to investment strategy

 

Braveheart Investment Group (AIM: BRH), announces that the Company's annual report and accounts for the year ended 31 March 2023, which incorporates notice of the Company's 2023 Annual General Meeting ("AGM") will be posted to shareholders today and will be available to download from the Company's website at www.braveheartgroup.co.uk.

 

The AGM will be held on 28 July 2023 at 10.30 am at the office of China Ventures Ltd, Unit 2, Common Farm, Common Lane, Mappleborough Green, Warwickshire, B80 7DP.

 

Proposed amendments to the Group's investment strategy

 

The AGM notice contains a resolution (the "Investment Strategy Resolution") to permit the Directors to replace the Company's investment strategy (the "Investment Strategy") as set out in part 1 of the Company's admission document dated 27 March 2007, which determines the permitted business and strategy of the Company.

 

The proposed new Investment Strategy is set out below:

 

The Group's strategy is to invest in early and later-stage businesses, primarily in the technology sector, but it will also consider opportunities in other sectors that are knowledge intensive, such as healthcare and professional services.

 

The Group will target investments in both unlisted and listed companies, where there is potential for significant growth. Investments are expected to be mainly in the form of equity and equity-related instruments, including convertible debt instruments in certain circumstances.

 

The Group may acquire investments directly or by way of holdings in intermediate holding or subsidiary entities. The Group might also invest in limited liability partnerships and other forms of legal entity. Where possible, the Group will seek investor protection rights, as determined by the Board.

 

The Group may offer its Ordinary Shares in exchange for shares in investee businesses in addition to a cash investment in such businesses.

 

For unlisted company investments, the Group targets companies at different stages of development, ranging from those which are just starting to trade to those which are expecting to achieve an IPO in the short term, thus providing portfolio diversification. These investments will typically involve active investment management.

 

The Group, where appropriate and deemed by the Board to be in the Group's best interests, may seek a position on the boards of unlisted investee companies. The Group where appropriate, will assist the board and management of investee companies, including helping to scale management teams, informing strategy and assisting with future financing.

 

For listed company investments, the Group targets investments where the Board considers the shares are undervalued but there are opportunities for significant growth. These investments will typically involve passive investment management, although the Board may take a more active approach if it considers there is a need to effect change.

 

Braveheart may occasionally invest in companies that are in rescue or distress situations where a value-creating opportunity has been identified. The Group does not have any maximum exposure limits but will generally take a minority stake in a business and look for investments where there is a good prospect of an exit in a two-to-five-year time period.

 

As risk reduces, the Group may increase its investment in subsequent rounds of funding and, as those businesses grow, may find itself holding a controlling interest in some trading companies. However, in such instances the Board will ensure that there is sufficient separation between the Group and the investee company so that the investee company does not become a trading company of the Group.

 

Full details of the proposed amendments to the Investment Strategy are set out in the explanatory notes to the notice of AGM. Should the Investment Strategy Resolution not be passed at the AGM, the Company will not be able to make the proposed amendments to the Investment Strategy. A further announcement will be made on conclusion of the AGM.

 

For further information:

Braveheart Investment Group plc

Tel: 01738 587555

Trevor Brown, Chief Executive Officer

Viv Hallam, Executive Director

Allenby Capital Limited (Nominated Adviser and Joint Broker)

Tel: 020 3328 5656

James Reeve / George Payne

Peterhouse Capital Limited (Joint Broker)

Tel: 020 7469 0936

Duncan Vasey / Lucy Williams

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOANKQBBNBKDCOK
Date   Source Headline
2nd Jun 20207:00 amRNSOperational update on Kirkstall Limited
1st Jun 20207:00 amRNSFurther re Paraytec Limited
29th May 20205:00 pmRNSTotal Voting Rights
21st May 20207:00 amRNSHolding in Phasefocus increased and other matters
20th May 20202:05 pmRNSSecond Price Monitoring Extn
20th May 20202:00 pmRNSPrice Monitoring Extension
20th May 202011:05 amRNSSecond Price Monitoring Extn
20th May 202011:00 amRNSPrice Monitoring Extension
20th May 20209:34 amRNSHolding(s) in Company
19th May 202012:48 pmRNSHolding(s) in Company
11th May 20208:51 amRNSHolding(s) in Company
11th May 20207:01 amRNSHolding(s) in Company
11th May 20207:00 amRNSHolding(s) in Company
7th May 20206:15 pmRNSHolding(s) in Company
6th May 20207:00 amRNSUpdate in response to social media speculation
4th May 20204:41 pmRNSSecond Price Monitoring Extn
4th May 20204:36 pmRNSPrice Monitoring Extension
4th May 20207:00 amRNSFurther re Kirkstall Limited
1st May 20207:00 amRNSFurther Placing to raise £350,000
29th Apr 20204:40 pmRNSSecond Price Monitoring Extn
29th Apr 20204:36 pmRNSPrice Monitoring Extension
29th Apr 20207:00 amRNSPlacing to raise £275,000
27th Apr 202011:05 amRNSSecond Price Monitoring Extn
27th Apr 202011:00 amRNSPrice Monitoring Extension
23rd Apr 20207:00 amRNSOperational update re certain investments
14th Apr 20207:00 amRNSOperational update on the Strategic Investments
3rd Mar 20207:00 amRNSOperational Update and Strategic Investments
30th Jan 20207:00 amRNSOperational update on Strategic Investments
12th Dec 20197:00 amRNSFurther investment in Pharm 2 Farm Limited
21st Nov 20197:00 amRNSOperational update on strategic investments
31st Oct 201910:55 amRNSHalf-year Report
28th Oct 20195:12 pmRNSFurther re buying remaining shares of Paraytec
19th Sep 20197:00 amRNSResults of customer trials by Pharm2Farm Limited
18th Sep 20197:00 amRNSDiscussions to buy remaining shares of Paraytec
29th Aug 201912:20 pmRNSResult of AGM
5th Aug 20197:00 amRNSPosting of annual accounts
1st Aug 20193:27 pmRNSREPLACEMENT: Final Results
1st Aug 20197:00 amRNSFinal Results
8th Jul 20197:00 amRNSInvestment in Pharm2Farm Limited
7th Jun 20197:00 amRNSUpdate to the Market
16th Apr 20197:00 amRNSDisposal of Viking Fund Managers Limited
12th Feb 201910:25 amRNSHolding(s) in Company
31st Jan 20195:17 pmRNSHolding(s) in Company
13th Dec 20187:00 amRNSFund Management Division Update
30th Oct 20187:00 amRNSInterim Results
18th Oct 201811:28 amRNSUpdate re Reduction of Share Capital
24th Sep 20189:00 amRNSConversion of Loan Notes in Paraytec Limited
4th Sep 20187:00 amRNSFurther re. Partial Disposal of Investment
21st Aug 20187:00 amRNSPartial Disposal of Investment in Gyrometric
19th Jul 201812:15 pmRNSResult of AGM and GM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.